| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(87)92159-3 |
| P698 | PubMed publication ID | 2883502 |
| P2093 | author name string | U Leibundgut | |
| I Lancranjan | |||
| P433 | issue | 8543 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1198 | |
| P577 | publication date | 1987-05-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis | |
| P478 | volume | 1 |
| Q35625453 | 5-HT3 antagonist ondansetron--an effective outpatient antiemetic in cancer treatment |
| Q36711373 | 5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis |
| Q48318685 | A novel series of N-(hexahydro-1,4-diazepin-6-yl) and N-(hexahydroazepin- 3-yl)benzamides with high affinity for 5-HT3 and dopamine D2 receptors |
| Q42492966 | A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic response |
| Q41901814 | A single-dose-finding study of the antiemetic effect and associated plasma levels of MDL 72222 in patients receiving cisplatin |
| Q54035467 | An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. |
| Q40231883 | Anticholinergic, antihistaminic, and antiserotonergic activity of n-hexane extract of Zanthoxylum alatum seeds on isolated tissue preparations: An ex vivo study. |
| Q38208999 | Anticipatory nausea in animal models: a review of potential novel therapeutic treatments |
| Q37039597 | Antiemetics: an update and the MASCC guidelines applied in clinical practice |
| Q42371534 | Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs |
| Q61694439 | Chapter 21. Gastrointestinal Motility Enhancing Agents |
| Q41791586 | Cisplatin induced emesis: preliminary results indicative of changes in plasma levels of 5-hydroxytryptamine |
| Q54280745 | Compassionate use of a 5-HT3-receptor antagonist, tropisetron, in patients refractory to standard antiemetic treatment |
| Q83952025 | Controlling chemotherapy-related nausea and vomiting |
| Q37084146 | Controlling emesis related to cancer therapy |
| Q38010671 | Developments in 5-hydroxytryptamine receptor pharmacology in migraine. |
| Q35981578 | Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret |
| Q93515830 | Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors |
| Q34532690 | Effect of ICS 205-930 (a specific 5-HT3 receptor antagonist) on gastric emptying of a solid meal in normal subjects |
| Q51619066 | Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides. |
| Q44335950 | Effects of 5-HT3 receptor antagonists on behavioural measures of naloxone-precipitated opioid withdrawal |
| Q41872523 | Effects of a 5-hydroxytryptamine3 receptor antagonist (ICS 205-930) on colonic motor activity in healthy men. |
| Q42093063 | Effects of the 5-HT3 receptor antagonist ICS 205-930 on fat-delayed gastric emptying and antral motor activity |
| Q42136434 | Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and Vomiting |
| Q77904056 | Nitrogen-containing heteroalicycles with serotonin receptor binding affinity: development of gastroprokinetic and antiemetic agents |
| Q61868420 | PREVENTION OF EMESIS IN PATIENTS RECEIVING CYTOTOXIC DRUGS BY GR38032F, A SELECTIVE 5-HT3 RECEPTOR ANTAGONIST |
| Q36466786 | Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist. |
| Q95811358 | Pharmacological Agents Affecting Emesis : A Review (Part II) |
| Q44628576 | Pharmacological properties of a novel class of 5-HT3 receptor antagonists |
| Q70688883 | Prevention of emesis by ICS 205-930 in children receiving cytotoxic chemotherapy |
| Q47309204 | Self-injury, regurgitation, and antiemetics |
| Q42601066 | The anti-emetic efficacy and tolerability of tropisetron in patients conditioned with high-dose chemotherapy (with and without total body irradiation) prior to bone marrow transplantation |
| Q36466782 | The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. |
| Q44645356 | The antiemetic profile of Y-25130, a new selective 5-HT3 receptor antagonist |
| Q24540442 | The effect on motion sickness and oculomotor function of GR 38032F, a 5-HT3-receptor antagonist with anti-emetic properties |
| Q43331108 | The effects of gamma-radiation on intestinal motor activity and faecal pellet expulsion in the guinea pig. |
| Q67541474 | Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients |
| Q48935254 | Topographical distribution of 5-HT3 receptor recognition sites in the ferret brain stem |
| Q40872768 | Tropisetron (ICS 205-930): a selective 5-hydroxytryptamine antagonist |
| Q40385730 | Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic |
| Q35332522 | Tropisetron. A review of the clinical experience |
| Q83944098 | [Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research] |
Search more.